The evaluation includes a thorax CT scan with intravenous contrast, a thoracoscopic pleural biopsy, and thoracentesis of pleural effusion, if present, with cytologic analysis.

Megakaryocyte potentiating factor is used as a serum biomarker for malignant pleural mesothelioma.

The cardiologist must clear all patients deemedÂ candidates for surgery. A stress test should be performed, and lung function should be optimized.